Heritage Trust Co lowered its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 1.9% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 93,034 shares of the company’s stock after selling 1,823 shares during the quarter. AbbVie comprises about 2.1% of Heritage Trust Co’s portfolio, making the stock its 8th largest position. Heritage Trust Co’s holdings in AbbVie were worth $24,337,000 at the end of the most recent reporting period.
Other large investors have also added to or reduced their stakes in the company. Verus Financial Partners Inc. raised its stake in shares of AbbVie by 1.7% in the third quarter. Verus Financial Partners Inc. now owns 2,048 shares of the company’s stock worth $536,000 after purchasing an additional 35 shares during the last quarter. Evergreen Private Wealth LLC lifted its holdings in shares of AbbVie by 3.3% during the third quarter. Evergreen Private Wealth LLC now owns 1,090 shares of the company’s stock worth $285,000 after purchasing an additional 35 shares during the period. Lifelong Wealth Advisors Inc. boosted its position in AbbVie by 2.1% in the third quarter. Lifelong Wealth Advisors Inc. now owns 1,755 shares of the company’s stock valued at $459,000 after buying an additional 36 shares during the last quarter. IMG Wealth Management Inc. boosted its position in AbbVie by 22.8% in the third quarter. IMG Wealth Management Inc. now owns 194 shares of the company’s stock valued at $51,000 after buying an additional 36 shares during the last quarter. Finally, Foundry Financial Group Inc. boosted its position in AbbVie by 4.6% in the third quarter. Foundry Financial Group Inc. now owns 839 shares of the company’s stock valued at $219,000 after buying an additional 37 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.
AbbVie News Roundup
Investors following ABBV have been watching these news items:
- Positive Sentiment: AbbVie reported positive Phase 3 results for QULIPTA in a migraine trial, a potential boost to its neuroscience portfolio and the drug’s growth prospects. AbbVie Reports Positive Phase 3 QULIPTA Migraine Trial Results
- Positive Sentiment: AbbVie’s immunology sales grew 16.6% in the third quarter, led by Skyrizi and Rinvoq. Their momentum is helping lift sales expectations for 2026, although Humira continues to decline. How Did AbbVie’s Immunology Franchise Fare in Q3?
- Positive Sentiment: AbbVie licensed Nxera Pharma’s EP4 agonist program for inflammatory bowel disease. The deal adds a potential pipeline asset, though its milestones depend on future development and other conditions. AbbVie Deal Altering the Investment Case for Nxera Pharma
AbbVie Stock Performance
ABBV stock opened at $295.18 on Monday. AbbVie Inc. has a one year low of $190.75 and a one year high of $302.93. The firm’s fifty day moving average is $275.51 and its 200 day moving average is $240.91. The firm has a market cap of $521.77 billion, a PE ratio of 50.81, a P/E/G ratio of 1.34 and a beta of 0.20.
AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings data on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, topping analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The business had revenue of $17.40 billion during the quarter, compared to the consensus estimate of $17.32 billion. During the same quarter in the prior year, the firm posted $1.86 earnings per share. The company’s revenue was up 10.3% compared to the same quarter last year. Research analysts predict that AbbVie Inc. will post 13.98 earnings per share for the current fiscal year.
AbbVie Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be issued a dividend of $1.82 per share. The ex-dividend date of this dividend is Friday, January 15th. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. This represents a $7.28 dividend on an annualized basis and a dividend yield of 2.5%. AbbVie’s payout ratio is currently 119.10%.
Insider Transactions at AbbVie
In related news, EVP Jeffrey Stewart sold 40,619 shares of the stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $293.60, for a total value of $11,925,738.40. Following the completion of the sale, the executive vice president owned 83,171 shares of the company’s stock, valued at approximately $24,419,005.60. This trade represents a 32.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.06% of the company’s stock.
Analyst Ratings Changes
A number of equities analysts have issued reports on the stock. Argus raised their price target on shares of AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. Wells Fargo & Company lifted their price objective on shares of AbbVie from $300.00 to $340.00 and gave the company an “overweight” rating in a research note on Monday, November 2nd. Erste Group Bank raised shares of AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Morgan Stanley increased their price objective on shares of AbbVie from $310.00 to $346.00 and gave the stock an “overweight” rating in a research note on Monday, November 2nd. Finally, Wolfe Research raised shares of AbbVie from a “peer perform” rating to an “outperform” rating and raised their target price for the stock from $235.00 to $300.00 in a report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $297.46.
Read Our Latest Research Report on AbbVie
AbbVie Company Profile
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
See Also
- Five stocks we like better than AbbVie
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
